453 results on '"Ball, Somedeb"'
Search Results
2. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML
3. Updates in biology, classification, and management of acute myeloid leukemia with antecedent hematologic disorder and therapy related acute myeloid leukemia
4. Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes
5. Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes
6. Mutations highly specific for secondary AML are associated with poor outcomes in ELN favorable risk NPM1-mutated AML
7. Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes
8. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion
9. Utilization of serial next-generation sequencing among patients receiving CPX-351 for newly diagnosed acute myeloid leukemia
10. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients
11. A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis
12. Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes.
13. Outcomes by Best Response With Hypomethylating Agent Plus Venetoclax in Adults with Previously Untreated Acute Myeloid Leukemia
14. Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib
15. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
16. Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy
17. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials
18. Breast cancer chemoprevention: An update on current practice and opportunities for primary care physicians
19. Management of Thrombotic Complications in COVID-19: An Update
20. Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials
21. Risk of kidney toxicity with carfilzomib in multiple myeloma: a meta-analysis of randomized controlled trials
22. Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week
23. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy
24. Drivers of deep molecular response and long‐term outcomes in patients with core binding factor acute myeloid leukemia
25. P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
26. MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3
27. MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
28. AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen
29. AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia
30. Microparticles in Hematological Malignancies: Role in Coagulopathy and Tumor Pathogenesis
31. Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients
32. Teaching NeuroImages: Extrapontine osmotic demyelination in hypernatremia
33. Depression in heart failure: Intricate relationship, pathophysiology and most updated evidence of interventions from recent clinical studies
34. Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms
35. Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion
36. Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML
37. Luspatercept for Treatment of Lower Risk Myelodysplastic Syndromes: Real World Data Replicates Medalist Study Results and Confirms Activity Among Hypomethylating Agents and Lenalidomide Treated Patients
38. The Prognostic Impact of FLT3 in NPM1-Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes
39. Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
40. Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes
41. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Therapy-Related Myelodysplastic Syndromes
42. A Product of "Clash of Titans" or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome
43. Hypoplastic MDS: Validation of the New World Health Organization 2022 Proposal
44. Characterization of TP53-Mutated Myelodysplastic Syndromes and Impact of Allelic Status and Concurrent Cytogenetic Abnormalities on Survival Outcomes
45. Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated with Hypomethylating Agent Plus Venetoclax Compared to CPX-351
46. Assessment of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model in Hypoplastic Myelodysplastic Syndromes
47. TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs
48. Poster: AML-488 Impact of Somatic Mutations on Treatment Response and Outcomes in Patients With Core Binding Factor Acute Myeloid Leukemia
49. Poster: AML-518 Gemtuzumab Ozogamicin in Patients With Newly Diagnosed Acute Myeloid Leukemia – Day 1 vs Day 1, 4 and 7 Regimen
50. Poster: MDS-519 Outcome Predictors and Timing Considerations for Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.